Viatris Pushes Back ‘Roadmap’ Reveal
Investor Event To Unveil Detailed Strategy Had Been Planned For 7 January
Viatris has delayed the big reveal of details of its two-phase strategic roadmap that had been due to take place at an investor event planned for early January.
You may also be interested in...
Biocon Biologics will pay up to $3.3bn to acquire the global biosimilars business of Viatris, in a long-rumored deal that will create a vertically-integrated biosimilars giant with annual sales approaching $1bn.
In February, key launches from Accord and Eagle are set to go ahead, while Viatris will host its delayed investor day and industry will meet in-person in Florida for the US Association for Accessible Medicines’ Access! event.
Ahead of the usual flurry of deal-making in January, Roche gets retinal cell therapy candidate from Lineage Cell Therapeutics, Pfizer subsidiary Amplyx licenses antiviral candidate to Vera, and GSK expands neurology tie-up with Ligand.